Cargando…

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?

Detalles Bibliográficos
Autores principales:	F., GALACTÉROS, E., VOSKARIDOU, A., HABIBI, G., CANNAS, L., JOSEPH, G., LOKO, M., DE MONTALEMBERT
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429612/ http://dx.doi.org/10.1097/01.HS9.0000873248.60171.71

Ejemplares similares

Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review
por: Flevari, Pagona, et al.
Publicado: (2022)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study
por: Habibi, Anoosha, et al.
Publicado: (2023)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

P090 Acceptability, Feasibility and Accuracy of Home Sleep Studies in Children with Neuromuscular Disorders
por: Pettigrew, G, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

P111: COVID-19 IN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: A SINGLE CENTER EXPERIENCE
por: Dimopoulou, M, et al.
Publicado: (2022)

P090: Importance of the information system in the fight against multi-drug resistant bacteria
por: Izoard, S, et al.
Publicado: (2013)

P090 The Effect of Workload, Sleep Deprivation and Time of Day on Simulated Driving Performance
por: Marando, I, et al.
Publicado: (2021)

P102: PLASMA FREE HEMOGLOBIN AND REACTIVE OXYGEN SPECIES IN SICKLE CELL ANAEMIA PATIENTS UNDER HYDROXYUREA AND GLUTAMINE THERAPY
por: Giannaki, A, et al.
Publicado: (2022)

P-007: HYDROXYUREA FOR THE MANAGEMENT OF SICKLE CELL DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW (2000–2022)
por: L., TSHILOLO, et al.
Publicado: (2022)

P-009: IDENTIFYING BARRIERS FOR PATIENTS WITH SICKLE CELL DISEASE TO ACCESS TREATMENT WITH HYDROXYUREA – A QUALITATIVE ANALYSIS OF THE SUPPLY CHAIN IN GHANA
por: S., GRAVEN, et al.
Publicado: (2022)

P1425: SYSTEMATIC INVESTIGATION OF HYDROXYUREA TREATMENT EFFECT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Bhat, Varsha, et al.
Publicado: (2023)

P090 How do Australian Shiftworkers and Non-Shiftworkers Prioritise Sleep, Diet, and Physical activity?
por: Gupta, C, et al.
Publicado: (2023)

P-028: CIRCULATING CD34+CD235A+ CELL COUNT CORRELATES WITH LEVELS OF HBF IN SICKLE CELL ANEMIA PATIENTS UNDER HYDROXYUREA TREATMENT
por: J., MILHOMENS, et al.
Publicado: (2022)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

O090: Impact on nurses of ebola outbreak
por: Pululu, D, et al.
Publicado: (2013)

P115: REAL-WORLD DATA ON THE EFFICACY OF PHARMACEUTICAL-GRADE L-GLUTAMINE IN PREVENTING SICKLE CELL DISEASE-RELATED ACUTE COMPLICATIONS AND HEMOLYSIS IN PEDIATRIC AND ADULT PATIENTS.
por: Elenga, N, et al.
Publicado: (2022)

P-027: SICKLE CELL DISEASE AND AUTOIMMUNE LIVER DISORDERS: SHOULD HEMATOPOIETIC STEM CELL TRANSPLANTATION BE DISCUSSED EARLY?
por: F., LACAILLE, et al.
Publicado: (2022)

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA
por: POWER-HAYS, A., et al.
Publicado: (2022)

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
por: A., CAMPOS, et al.
Publicado: (2022)

P-018: MILESTONES ALONG MY PERSONAL JOURNEY WITH HYDROXYUREA
por: A., SHAKIR
Publicado: (2022)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA
por: Brito, M., et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

AB090. Biallelic and triallelic 5-HTTLPR polymorphisms and their relationship with lifelong premature ejaculation: a case-control study from a Chinese population
por: Peng, Dangwei
Publicado: (2016)

P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
por: A., IDRIZOVIC, et al.
Publicado: (2022)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

P1489: MANAGEMENT OF SICKLE CELL DISEASE WITH HYDROXYUREA: A SYSTEMATIC REVIEW FROM LOW- AND MIDDLE-INCOME COUNTRIES
por: Paintsil, V., et al.
Publicado: (2022)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

P1446: HYDROXYUREA AND LIMB ULCERS: IS IT WORTH SUSPENDING? RETROSPECTIVE COHORT STUDY OF BRAZILIAN ADULT PATIENTS WITH SICKLE CELL DISEASE
por: Benites, Bruno, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Evaluation of a patient-dedicated blood gas analyser
por: Fox, JJ, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_heceko1ftd7ath7sfm68b712df